Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
An innovative treatment for your patients living with HIV
Powerful, Durable Efficacy¹,²
TDF, TAF and ABC Free¹
Dovato Recommended in Treatment Guidelines
EACS Guidelines 2020
Recommended as an initial regimen for treatment-naïve patients and as a switch strategy for virologially suppressed patients⁴
- Requirements for treatment-naïve patients:
- HBsAG negative
- HIV viral load <500,000 copies/mL
DHHS Guidelines 2019
Recommended as an initial regimen for most PLHIV (AI)* as a good option for virologically suppressed patients who have no evidence of resistance to either drug⁵
- Exclusions for treatment-naïve patients:
- HIV viral load >500,000 copies/mL
- HBV co-infection
- Where ART is to be started before the results of HIV genotype resistance testing for reverse transcriptase or HBV testing are available.
Resources for you and your patients
* Rating of recommendations: A= strong; B= moderate; C= optional. Rating of evidence: I= data from randomised controlled trials; II= data from well-designed non-randomised trials, observational cohort studies with long-term clinical outcomes, relative bioavailability / bioequivalence studies, or regimen comparisons from randomised switch studies; III= expert opinion.⁵
References:
- Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-navie adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquired Immune Defic Syndr. 2020;83(3):310-318.
- Van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomised noninferioity TANGO study. Clin Infect Dis. 2020. doi:10.1093/cid/ciz1243.
- Dovato Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/dovato-50-mg-300-mg-film-coated-tablets-34871/smpc. Last Accessed October 2021.
- European AIDS Clinical Society Guidelines. Version 10.1. October 2020. Last Accessed October 2021.
https://www.eacsociety.org/guidelines/eacs-guidelines/
- US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Last Accessed October 2021. Updated December 18, 2019. https://hivinfo.nih.gov/home-page
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.
Date of preparation: January 2022 PM-IE-DLL-WCNT-200015
